4LH-16248-73478
4 vaccinations
4 coded responses
55 check-ins
3 free-text entries
0 call cases
- Sex
- Female
- Age at first dose
- 31-35
- ZIP prefix
- 971 / OR
- Registered
- 2021-01-04
- Relationship
- Self
- Race
- White
- Ethnicity
- Not Hispanic or Latino
Timeline
-
2021-01-04
Registered in v-safe
-
2021-01-04
Dose 1 — Moderna
- 2021-01-04
-
2021-01-05
Survey response — days 1–6 daily, dose 1MedDRA: Injection site mass — Feeling: Good · Site: Pain, RednessFree text: There is a palpable mass at the injection site.MedDRA releases: 2021-09,2023-04,2024-11 · check-in free text available
-
2021-01-06
Health check-in — days 1–6 daily, dose 1Feeling: Good · Site: Redness, Swelling · NoneAdult check-in
- 2021-01-07
- 2021-01-08
- 2021-01-09
- 2021-01-10
- 2021-01-11
- 2021-01-18
- 2021-01-25
-
2021-01-29
Dose 2 — Moderna
- 2021-01-29
-
2021-01-30
Health check-in — days 1–6 daily, dose 2Feeling: Fair · Site: Pain · Headache, Muscle or body aches, Fatigue or tirednessAdult check-in
-
2021-01-31
Survey response — days 1–6 daily, dose 2MedDRA: Lymphadenopathy — Feeling: Fair · Site: Pain, Swelling · Fever · Chills, Headache, Muscle or body achesFree text: Lymphnode involvementMedDRA releases: 2021-09,2023-04,2024-11 · check-in free text available
- 2021-02-01
- 2021-02-02
- 2021-02-03
- 2021-02-04
- 2021-02-05
- 2021-02-12
- 2021-02-19
- 2021-02-26
- 2021-03-05
- 2021-03-12
- 2021-04-30
-
2021-07-30
Survey response — 6 months, dose 2MedDRA: Hypersensitivity, SARS-CoV-2 test negative — Feeling: Good · Be unable to work or attend schoolFree text: Allergy attack, was tested for covid, was negativeMedDRA releases: 2021-09,2024-11 · check-in free text available
-
2021-10-27
Dose 3 — Moderna
- 2021-10-27
-
2021-10-28
Health check-in — days 1–6 daily, dose 3Feeling: Poor · Site: Pain, Redness, Swelling · Fever · Chills, Headache, Joint pains, Muscle or body aches, Fatigue or tiredness, Nausea · Be unable to work or attend school, Be unable to do your normal daily activitiesAdult check-in
- 2021-10-29
- 2021-10-30
- 2021-10-31
- 2021-11-01
- 2021-11-02
- 2021-11-03
- 2021-11-10
- 2021-11-17
- 2021-11-24
- 2021-12-01
- 2021-12-08
- 2022-01-26
- 2022-04-27
-
2022-06-30
Dose 4 — Pfizer-BioNTech
-
2022-07-01
Health check-in — days 1–6 daily, dose 4Feeling: Fair · Site: Pain · Joint pains, Muscle or body aches, Fatigue or tirednessAdult check-in
- 2022-07-02
- 2022-07-03
- 2022-07-04
- 2022-07-05
- 2022-07-06
- 2022-07-07
- 2022-07-14
- 2022-07-21
- 2022-07-28
- 2022-08-04
- 2022-08-11
- 2022-09-29
- 2022-12-29
-
2023-06-30
Survey response — 12 months, dose 4MedDRA: Nasopharyngitis — Feeling: Fair · Be unable to work or attend schoolMedDRA releases: 2024-11
Vaccinations
| Dose | Date | Manufacturer | Co-administered |
|---|---|---|---|
| 1 | 2021-01-04 | Moderna | |
| 2 | 2021-01-29 | Moderna | |
| 3 | 2021-10-27 | Moderna | No |
| 4 | 2022-06-30 | Pfizer-BioNTech | No |
Free text
Release 1 — days 1–6 daily, dose 1
Systemic reaction (other): There is a palpable mass at the injection site.
Release 3 — days 1–6 daily, dose 2
Systemic reaction (other): Lymphnode involvement
Release 9 — 6 months, dose 2
Symptoms: Allergy attack, was tested for covid, was negative
Each entry is dated by the survey it was written in (the CDC re-sent the releases with survey dates in 2025); click a date to see that survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".
MedDRA terms by release
| Field | Preferred term | 2021-09 | 2023-04 | 2024-11 |
|---|---|---|---|---|
| SD | Hypersensitivity | ✓ | · | ✓ |
| SD | Nasopharyngitis | · | · | ✓ |
| SD | SARS-CoV-2 test negative | ✓ | · | ✓ |
| SRO | Injection site mass | ✓ | ✓ | ✓ |
| SRO | Lymphadenopathy | ✓ | ✓ | ✓ |
✓ active code · ○ coded but marked inactive · blank = not in that release